Directorate Change

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces the resignation of Stella Panu as a Non-Executive Director of the Company, effective from 15 April 2024.

Following the fundraise in January 2024, Stella has decided to step down from the Board of ValiRx to concentrate on her other commitments. Stella has agreed to a 3-month handover period to allow sufficient time for the Board to identify an appropriate replacement and ensure a smooth transition of responsibilities.

During Stella's tenure as a Non-Executive Director, she has made significant contributions to the development of the strategy and the changes required to ensure the Company achieves its longer-term growth goals. Stella's expertise and guidance have been invaluable, and the Company would like to express its gratitude for her dedicated service.

With Stella's support, the Company will be working diligently to identify a suitable candidate to fill the vacancy created by her departure. In particular, the Board will be seeking candidates with a background in early-stage pharmaceutical development, aligning with our strategic focus. The Board and management are committed to ensuring a seamless transition and will work closely with Stella to facilitate a comprehensive handover of duties.

Kevin Cox, Chairman of ValiRx commented "I would very much like to extend my sincere appreciation to Stella for her invaluable contributions to ValiRx over the past years. Her knowledge and skills have been instrumental in the successful acquisition of Imagen Therapeutics assets, which have provided a significant milestone in the development of Inaphaea Biolabs. Her presence on the Board and guidance to me will be greatly missed, and I wish her continued success in future endeavours."

The Directors of the Company take responsibility for this announcement.